Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

Fms-related-tyrosine kinase 3 (FLT3) mutations occur in approximately a third of acute myeloid leukemia (AML) patients and confer an adverse prognosis. Numerous studies have evaluated FLT3 targeting as single agent and in combination approaches in frontline and relapsed AML. At this time, midostauri...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Hussein A, Alfayez, Mansour, Kadia, Tapan, Ravandi-Kashani, Farhad, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6782026/
https://www.ncbi.nlm.nih.gov/pubmed/31632141
http://dx.doi.org/10.2147/CMAR.S177894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6782026/
https://www.ncbi.nlm.nih.gov/pubmed/31632141
http://dx.doi.org/10.2147/CMAR.S177894

Ejemplares similares